NasdaqGS:ADPTLife Sciences
Assessing Adaptive Biotechnologies (ADPT) Valuation After 2025 Results And 2026 MRD Guidance
Why Adaptive Biotechnologies Stock Is Back in Focus
Adaptive Biotechnologies (ADPT) is drawing attention after reporting full year 2025 results, with sales of US$276.98 million, a net loss of US$59.5 million, and fresh 2026 revenue guidance for its MRD business.
See our latest analysis for Adaptive Biotechnologies.
The earnings release and 2026 MRD revenue guidance appear to be a key backdrop for recent trading. The share price is US$16.04, with a 3.22% 1-day share price return and a 13.76%...